The estimated Net Worth of Ashley Cordova is at least $6.16 Millón dollars as of 2 August 2024. Ms Cordova owns over 688 units of NovoCure Ltd stock worth over $3,776,454 and over the last 4 years she sold NVCR stock worth over $1,389,162. In addition, she makes $995,202 as CFO & VP of Investor Relations at NovoCure Ltd.
Ms has made over 20 trades of the NovoCure Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 688 units of NVCR stock worth $13,856 on 2 August 2024.
The largest trade she's ever made was exercising 36,624 units of NovoCure Ltd stock on 12 August 2021 worth over $1,055,504. On average, Ms trades about 2,791 units every 47 days since 2020. As of 2 August 2024 she still owns at least 219,179 units of NovoCure Ltd stock.
You can see the complete history of Ms Cordova stock trades at the bottom of the page.
Ashley Cordova is the CFO & VP of Investor Relations at NovoCure Ltd.
As the CFO & VP of Investor Relations of NovoCure Ltd, the total compensation of Ms Cordova at NovoCure Ltd is $995,202. There are 9 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Ms Cordova is 42, she's been the CFO & VP of Investor Relations of NovoCure Ltd since . There are 22 older and 1 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Ashley's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... y Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: